Previous 10 | Next 10 |
FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma (INO), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), Ocu...
Initiating its coverage on COVID shot maker Ocugen (NASDAQ:OCGN) Cantor Fitzgerald argued on Thursday that even a small share of the U.S. COVID-19 vaccine market can lead to meaningful sales for the clinical-stage biotech. Ocugen (OCGN) has partnered with Bharat Biotech to introduce an inacti...
Cantor Fitzgerald initiates Ocugen (OCGN) +12% with overweight. Cantor's rating agrees with the Sell Side Rating of Buy (1 Very Bullish, 1 Bullish, 2 Neutral). It contrasts with SA Authors' average rating of Sell and Quant Rating of Strong Sell, based o...
Ocugen (NASDAQ: OCGN) has given vaccine investors a roller0coaster ride over the past year or so. It started out by soaring more than 700% in a few days after saying it would co-commercialize Bharat Biotech's coronavirus vaccine candidate -- Covaxin -- in the U.S. But as the project...
The Nasdaq bear market has seen many once-promising growth stocks tumble heavily this year. It has created some great buying opportunities in the markets for long-term investors. However, there are some stocks I'm not confident will recover anytime soon, and that investors are probably ...
If you’re shopping for a wallet and one comes complete with $100 worth of cash inside, and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market...
The clinical-stage biotech Ocugen (NASDAQ:OCGN) announced its cell therapy platform technology, NeoCart, on Tuesday after the FDA awarded the Regenerative Medicine Advanced Therapy (RMAT) designation for the program in the repair of knee cartilage lesions in adults. The company has engaged th...
NeoCart ® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines MALVERN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discoveri...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen (NASDAQ: OCGN ) stock is down despite news that the FDA is allowing it to proceed with clinical trials of its Covid-19 vaccine candidate This news lifts a significant hurdle that had been holding the company...
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...